LLY is trading at $1060.52 (+3.21%), significantly outperforming a modestly lower market, driven by continuing momentum in its obesity drug portfolio (Zepbound/Mounjaro) and recent strong analyst upgrades.
- The stock's resilience comes despite the S&P 500 being down 0.09% and the NASDAQ down 0.39%.
- The current price continues the recent uptrend, rising from $1014 recorded on December 4.
- A minor analyst price target cut by BofA Securities (from $1286 to $1268) was noted, though the "Buy" rating remains intact.